Here are relevant reports on : ovulation-predictor-kits-market
-
Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2030
The global Tissue Diagnostics market, valued at USD 6.19 billion in 2024, stood at USD 6.74 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of USD10.86 billion by the end of the period. The market growth is driven by the rising incidence of cancer and the growing demand for digital pathology, which are fueling the need for more accurate and high-throughput tissue-based diagnostics.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Reporter Gene Assay Market by Reagents & Assay kits (Luciferase, Green Fluorescent Protein, â-glucuronidase, â-galactosidase), Application (Gene Regulation, Protein Interaction, Cell Signalling Pathways), End Users, Region - Global Forecast to 2024
The reporter gene assay market is projected to reach USD 2.6 billion by 2024, at a CAGR of 10.1%. Factors contributing to the growth of this market include increasing funding for cell-based research, growing applications of gene expression, and rising preference for cell-based assays. The prominent players in the reporter gene assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Danaher Corporation (US), Geno Technology (US), Genecopoeia, Inc. (US), InvivoGen (France), PromoCell (Germany), Becton, Dickinson and Company (US), Biotium, Inc. (US), Canvax (Spain), LI-COR, Inc. (US), System Biosciences, LLC (US), Indigo Biosciences, Inc. (US), BioThema (Sweden), Takara Bio Inc (US), BioAssay Systems (US), Cell Biolabs, Inc. (US), BPS Bioscience, Inc (US), Biosynth AG (Switzerland), and Cayman Chemical (US).
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Europe In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Europe in vitro diagnostics (IVD) market, valued at USD 31.43 billion in 2025, stood at USD 33.83 billion in 2026 and is projected to advance at a resilient CAGR of 7.9% from 2026 to 2031, culminating in a forecasted valuation of USD 49.49 billion by the end of the period. Market growth is driven by rising diagnostic test volumes across national healthcare systems, broader adoption of population-based screening programs, and increasing emphasis on standardized disease monitoring.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Rapid Microbiology Testing Market by Product (Instruments (Automated Identification System, PCR, Mass Spectrometer) Reagent, Kits), Method (Growth, Nucleic Acid, Viability), Application (Clinical Diagnosis, Industrial, Research) & Region - Global Forecast to 2029
The global rapid microbiology testing market, valued at US$4.7 billion in 2023, stood at US$5.1 billion in 2024 and is projected to advance at a resilient CAGR of 10.1% from 2023 to 2029, culminating in a forecasted valuation of US$8.3 billion by the end of the period.The increasing use of rapid microbiology testing products can be attributed to their ability to provide quick and reliable results. These products are cost-effective and can often lead to cost savings compared to traditional methods, which is a significant factor driving market growth.
- Published: April 2024
- Price: $ 4950
- TOC Available:
-
High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030
Global high content screening market valued at $1.47B in 2024, reached $1.52B in 2025, and is projected to grow at a robust 7.5% CAGR, hitting $2.19B by 2030. Market growth in the Asia Pacific can be attributed to the increased pharmaceutical and biotechnology investments and the rising demand for personalized medicine.
- Published: April 2025
- Price: $ 4950
- TOC Available:
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market, valued at US$3.3 billion in 2022, stood at US$3.5 billion in 2023 and is projected to advance at a resilient CAGR of 10.6% from 2023 to 2028, culminating in a forecasted valuation of US$5.8 billion by the end of the period. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Cell-free Protein Synthesis Market by Offering (Cell Extract Systems (Prokaryotic, Mammalian, Plant), Kits, Instruments, Services), Workflow, Method (Coupled TX/TL, Transcription, Translation), Application (Protein Purification) - Global Forecast to 2030
The global cell-free protein synthesis market, valued at US$203.9 million in 2024, stood at US$217.2 million in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2024 to 2030, culminating in a forecasted valuation of US$308.9 million by the end of the period. Market growth is driven by increasing demand for biologics, vaccines, and personalized medicine, advancements in CFPS technologies, the need for quick prototyping of complex proteins, and the demand for commercial-scale validation of cell-free protein expression systems.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029
The global DNA diagnostics market, valued at US$12.3 billion in 2023, stood at US$13.3 billion in 2024 and is projected to advance at a resilient CAGR of 9.7% from 2024 to 2029, culminating in a forecasted valuation of US$21.2 billion by the end of the period. Growth in the market is primarily driven by the technological improvements in the DNA diagnostics industry and the growing need for personalized treatment and early disease diagnosis in developing nations. Also, the increased investments by healthcare-based companies are majorly contributing to growth of the market.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030
The global molecular cytogenetics market, valued at US$0.97 billion in 2024, stood at US$1.02 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2030, culminating in a forecasted valuation of US$1.43 billion by the end of the period. The market growth is fueled by increasing incidence of cancer & genetic disorders and rising usage of molecular cytogenetics in clinical pathology testing.
- Published: October 2025
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
